Pathalys Pharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Pathalys Pharma, Inc. - overview
Established
2021
Location
Raleigh, NC, US
Primary Industry
Biotechnology
About
Based in North Carolina, US, and founded in 2021, Pathalys Pharma, Inc. provides treatment for end-stage renal disease. As of 2024, the company is headed by its CEO Neal Fowler. In January 2023, the firm raised an amount of venture funding led by investor Abingworth, with participation from other investors Carlyle Group and OrbiMed Advisors.
Returning investors Catalys Pacific and DaVita Venture Group also participated in the round. The round was part of a larger USD 150 million equity and debt financing. The company offers solutions for patients with end-stage kidney disease. Pathalys provides calcimimetics for the treatment of SHPT.
By activating the calcium-sensing receptor, which is expressed in a variety of human organ tissues, calcimimetic is a medication that simulates the effects of calcium on tissues.
Current Investors
Catalys Pacific, DaVita Venture Group, Abingworth
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceuticals
Website
www.pathalys.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.